This presentation will discuss the use of recombinant bone morphogenetic protein-2 (rhBMP-2) to augment the maxillary sinus floor. Results will be presented from a pivotal trial comparing autologous bone grafts to rhBMP-2 at a dose of 1.50mg/ml. The objectives of this study were to assess the effectiveness of rhBMP-2/absorbable collagen sponge (ACS) to induce bone formation, for this bone to support dental implant restorations under a functional load, and to evaluate the safety of the rhBMP-2/ACS in a two-stage maxillary floor sinus augmentation procedure. Periodontal and oral and maxillofacial surgeons participated in this multi-center study. The results indicate that rhBMP-2/ACS was efficacious when used for maxillary floor augmentation procedures. The primary efficacy analysis was positive with a 79% success rate for functionally loaded implants. The rhBMP-2 was deemed safe, and the adverse events in both groups were similar. It appears that rhBMP-2 is a reliable alternative to autologous bone graft for sinus floor grafting. The material is cleared for orthopedic indications in the spine and is awaiting action by the FDA for oral indications.
R. Gilbert Triplett, DDS, PhD, is Regents Professor and chairman of the Department of Oral and Maxillofacial Surgery/Pharmacology at Baylor College of Dentistry, Texas A&M University System Health Science Center in Dallas. Dr Triplett has maintained a long-term interest in reconstruction of edentulism, implant dentistry, and bone regeneration.